Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Not Yet Opened 02-19 16:00:00 EST

15.97

+0.97

+6.47%

盘后15.97

+0.000.00%

17:47 EST

High16.62	Low14.43	Vol624.04K
Open14.89	D1 Closing15.00	Amplitude14.60%
Mkt Cap295.65M	Tradable Cap185.28M	Total Shares18.51M
T/O9.89M	T/O Rate5.38%	Tradable Shares11.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":15.97,"timestamp":1771534800000,"preClose":15,"halted":0,"volume":624044,"hourTrading":{"tag":"盘后","latestPrice":15.97,"preClose":15.97,"latestTime":"17:47 EST","volume":568,"amount":9071.14,"timestamp":1771541237369,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0646666666666667,"floatShares":11601900,"shares":18512800,"eps":-8.742119,"marketStatus":"Not Yet Opened","change":0.97,"latestTime":"02-19 16:00:00 EST","open":14.89,"high":16.62,"low":14.43,"amount":9885412.35916,"amplitude":0.146,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.742119,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771578000000},"marketStatusCode":0,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":15,"postHourTrading":{"tag":"盘后","latestPrice":15.97,"preClose":15.97,"latestTime":"17:47 EST","volume":568,"amount":9071.14,"timestamp":1771541237369,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.603289,"impliedVol":0.9389,"impliedVolPercentile":0.4953},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"2612642984","title":"Avalo Therapeutics Grants 82,000 Inducement Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2612642984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612642984?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:05","pubTimestamp":1771448723,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics granted two new employees nonstatutory stock options covering a total of 82,000 shares, with an exercise price of $14.26 per share. The options vest 25% on the one-year anniversary of each employee’s start date, with the remaining shares vesting monthly over the next 36 months, subject to continued service. The awards were granted under Avalo’s 2025 Inducement Award Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL2rhlcj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","AVTX","LU2210149790.SGD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2612769426","title":"Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612769426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612769426?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:05","pubTimestamp":1771448702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUABP920B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2608310364","title":"Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608310364","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608310364?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:57","pubTimestamp":1770209860,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Avalo Therapeutics today and set a price target of $48.00. According to TipRanks, R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-avalo-therapeutics-avtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-avalo-therapeutics-avtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX"],"gpt_icon":0},{"id":"2608366326","title":"Avalo Therapeutics nimmt an Investorenkonferenzen teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2608366326","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608366326?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206445,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. wird am 11. Februar 2026 am Guggenheim Emerging Outlook: Biotech Summit teilnehmen und am 25. Februar 2026 am Oppenheimer 36th Annual Healthcare Life Sciences Conference vertreten sein.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL6H8J6b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","AVTX","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2608656892","title":"Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2608656892","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608656892?lang=en_us&edition=fundamental","pubTime":"2026-02-03 03:25","pubTimestamp":1770060300,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics completed Phase 2 enrollment for AVTX-009, with mid-2026 data ahead. Cantor sees major upside if results impress, but warns shares could plunge if the trial disappoints.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/02/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/02/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","BK4581","BK4539","AVTX","XBI","BK4139","BK4007","BK4588","LENZ"],"gpt_icon":0},{"id":"2608895800","title":"This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2608895800","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608895800?lang=en_us&edition=fundamental","pubTime":"2026-02-03 00:04","pubTimestamp":1770048240,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.\nConsidering buying AVTX stock? Here’s what analysts think: \nPhoto via Shutterstock","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/02/Analyst-Works-On-Personal-Computer-Showi.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/02/Analyst-Works-On-Personal-Computer-Showi.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/02/50304704/this-avalo-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/02/50304704/this-avalo-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4112","BK4007","BK4539","AVTX","BK4139"],"gpt_icon":0},{"id":"2608886740","title":"Avalo Therapeutics Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608886740?lang=en_us&edition=fundamental","pubTime":"2026-02-02 22:34","pubTimestamp":1770042840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 09:34 ET (14:34 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","AVTX","BK4007"],"gpt_icon":0},{"id":"2608863597","title":"Avalo Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2608863597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608863597?lang=en_us&edition=fundamental","pubTime":"2026-02-02 19:15","pubTimestamp":1770030916,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $50 price target Published first on TheFly – the ultimate source f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","AVTX","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2602900316","title":"Avalo Therapeutics Files $750 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2602900316","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602900316?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:54","pubTimestamp":1767912852,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics  filed a registration statement late Thursday for the sale of $750 million of securities from time to time.The securities cover common and preferred stocks, debt securities, warrants, and units.Net proceeds will be used for general corporate purposes, according to the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","LENZ","AVTX","BK4007"],"gpt_icon":0},{"id":"2602318914","title":"BRIEF-Avalo Therapeutics Files For Mixed Shelf Of Up To $750 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318914","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318914?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:10","pubTimestamp":1767906651,"startTime":"0","endTime":"0","summary":"BRIEF-Avalo Therapeutics Files For Mixed Shelf Of Up To $750 Million - SEC FilingJan 8  - Avalo Therapeutics Inc AVTX.O:AVALO THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $750 MILLION - SEC FILINGSource text: [ID:n0001104659-26-002118]Further company coverage: AVTX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2602318733","title":"Avalo Therapeutics files $750M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318733?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906335,"startTime":"0","endTime":"0","summary":"16:03 EST Avalo Therapeutics (AVTX) files $750M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-files-750m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-files-750m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","AVTX","BK4007"],"gpt_icon":0},{"id":"2602131835","title":"Avalo Therapeutics Inc Files for Mixed Shelf of up to $750 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602131835","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602131835?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:02","pubTimestamp":1767906145,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPT","LU1989763690.USD","LU0234570918.USD","AXTA","CBT","SG9999001176.USD","CLYM","ASH","DOW","CRL","DD","HOUS","LU0345769631.USD","ACM","AVTX","ALB","AJG","ACHC","AAL","BCAX","BK4090","BK4107","CGNX","CMI","BAC","BK4147","BRO","AMRZ","COUR","CE","BBNX","ALSN","CTVA","APD","DAL","IE00B7SZLL34.SGD","AMAT","BTSG","SGXZ57979304.SGD","DG","CLW","CF","AZO","BSX","BIIB","ACAD","BK4548","ALL","ARDT","CL"],"gpt_icon":0},{"id":"2588032991","title":"Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2588032991","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588032991?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:08","pubTimestamp":1764673713,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa , addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7TL2xg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2581868717","title":"Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?","url":"https://stock-news.laohu8.com/highlight/detail?id=2581868717","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581868717?lang=en_us&edition=fundamental","pubTime":"2025-11-08 21:21","pubTimestamp":1762608092,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/will-avalo-therapeutics-nasdaqavtx-spend-its-cash-wisely","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/will-avalo-therapeutics-nasdaqavtx-spend-its-cash-wisely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","USAW.SI","QLD",".IXIC","NQmain","BK4139","USJW.SI","NVIW.SI","QID","TQQQ","MNQmain","SQQQ","AVTX","TSYW.SI"],"gpt_icon":1},{"id":"2581067246","title":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067246?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:18","pubTimestamp":1762431500,"startTime":"0","endTime":"0","summary":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment completeOverviewAvalo Therapeutics Q3 net loss misses analyst expectationsOperating expenses rose due to Phase 2 LOTUS trial costsCompleted e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2581062491","title":"Avalo Therapeutics reports third quarter revenue of zero dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062491?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:02","pubTimestamp":1762430566,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. reported cash, cash equivalents, and short-term investments of $111.6 million as of September 30, 2025. Net cash used in operating activities was $37.2 million for the nine months ended September 30, 2025. The company expects its current cash resources to fund operations into 2028. Product revenue for the third quarter and nine months ended September 30, 2025, was zero, compared to $0.2 million for the same periods in 2024. Recent business developments include the completion of enrollment in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa, with topline data expected in mid-2026, and the appointment of Kevin Lind to the Board of Directors, as well as new leadership in business development and human resources.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1qnlQg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","AVTX","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4585","LU2210150020.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2581706720","title":"Avalo Therapeutics: Cash & Short-Term Investments of About $112 Mln as of Sept 30, Expected to Provide Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706720?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA997Z3M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2581438064","title":"Avalo Therapeutics Q3 Operating Expenses USD 19.198 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581438064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581438064?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX39DC11:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2581064037","title":"Press Release: Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064037","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581064037?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430400,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment. -- Expanded leadership team with key appointments in business development. -- Cash and short-term investments of approximately $112 million as of. September 30, 2025 expected to provide runway into 2028. WAYNE, Pa., Nov. 06, 2025  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company fully dedicated to developing IL-1<BETA>-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the third quarter of 2025.\"Now that enrollment is complete, we're fully focused on completing the LOTUS trial, preparing for the data readout in mid-2026, and progressing our Phase 3 planning,\" said Dr. Garry Neil, Chief Executive Officer. \"This marks an important transition for Avalo as we turn our focus from enrollment to completion of the trial, guided by strong conviction in AVTX-009's high-affinity inhibition of IL-1<BETA> and its potential to deliver m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AVTX","BK4139","BK4007","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":0.0453},{"period":"1month","weight":-0.004},{"period":"3month","weight":-0.1545},{"period":"6month","weight":0.5182},{"period":"1year","weight":1.1157},{"period":"ytd","weight":-0.174}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.025561},{"month":3,"riseRate":0.3,"avgChangeRate":0.322911},{"month":4,"riseRate":0.3,"avgChangeRate":-0.087519},{"month":5,"riseRate":0.3,"avgChangeRate":-0.069789},{"month":6,"riseRate":0.7,"avgChangeRate":0.011587},{"month":7,"riseRate":0.5,"avgChangeRate":0.025049},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction